HARISH GOYAL: Open Payments
NPI 1558517391 · VIENNA, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$970 in 40 payments from 13 companies in 2025. Trend: 2023 $564 · 2024 $986 · 2025 $970
Food & beverage: $970
| Company | Payments | Amount |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 8 | $181 |
| Janssen Pharmaceuticals, Inc | 3 | $159 |
| Axsome Therapeutics, Inc. | 6 | $123 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $96 |
| Lundbeck LLC | 3 | $87 |
| E.R. Squibb & Sons, L.L.C. | 3 | $67 |
| Otsuka America Pharmaceutical, Inc. | 3 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $52 |
| Bausch Health US, LLC | 3 | $51 |
| Corium, LLC | 1 | $31 |
Products named: Qelbree, SPRAVATO, REXULTI, Auvelity, CAPLYTA, COBENFY, TRINTELLIX, APLENZIN.
Industry payments across VA — which companies pay providers there.
